Literature DB >> 17412885

CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).

Shahram Y Kordasti1, Wendy Ingram, Janet Hayden, David Darling, Linda Barber, Behdad Afzali, Giovanna Lombardi, Marcin W Wlodarski, Jaroslaw P Maciejewski, Farzin Farzaneh, Ghulam J Mufti.   

Abstract

Foxp3+ regulatory T cells (Tregs) play a central role in maintaining immune tolerance. A reduction in the function of Tregs is a key feature of autoimmune diseases, whereas their expansion in malignant diseases leads to the suppression of host antitumor responses. We analyzed the absolute number of CD4+ and CD8(+) Tregs in the peripheral blood of 52 patients with myelodysplastic syndrome (MDS) and show a significant correlation between increased number of CD4+ Tregs and MDS subgroups with 5% or more bone marrow blasts (P < .001), high International Prognostic Scoring System (IPSS) score (P < .001), and disease progression (P < .001), whereas no correlation between CD8+ Tregs and prognostic variables was observed. The CD4+ Tregs showed a polyclonal spectratype, and the percentage of the naive subset was significantly higher in the high-risk patients compared with low-risk or healthy age-matched donors (P = .032). Our data suggest that CD4+ Treg expansion is a feature of high-risk MDS and progression to aggressive subtypes of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412885     DOI: 10.1182/blood-2007-01-067546

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  88 in total

Review 1.  The inflammatory microenvironment in MDS.

Authors:  Lili Yang; Yaqin Qian; Erika Eksioglu; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Cell Mol Life Sci       Date:  2015-02-08       Impact factor: 9.261

2.  T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

Authors:  Elaine M Sloand; J Joseph Melenhorst; Zachary C G Tucker; Loretta Pfannes; Jason M Brenchley; Agnes Yong; Valeria Visconte; Colin Wu; Emma Gostick; Phillip Scheinberg; Matthew J Olnes; Daniel C Douek; David A Price; A John Barrett; Neal S Young
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

3.  Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.

Authors:  Xingmin Feng; Sachiko Kajigaya; Elena E Solomou; Keyvan Keyvanfar; Xiuli Xu; Nalini Raghavachari; Peter J Munson; Thomas M Herndon; Jichun Chen; Neal S Young
Journal:  Blood       Date:  2008-02-04       Impact factor: 22.113

4.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Authors:  Martine E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

Review 5.  Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.

Authors:  A John Barrett; Elaine Sloand
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941

6.  Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.

Authors:  Asaka Kondo; Taishi Yamashita; Hideto Tamura; Wanhong Zhao; Takashi Tsuji; Masumi Shimizu; Eiji Shinya; Hidemi Takahashi; Koji Tamada; Lieping Chen; Kazuo Dan; Kiyoyuki Ogata
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

7.  Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes.

Authors:  Josephine D Kahn; Martine E D Chamuleau; Theresa M Westers; Peter M Van de Ven; Linda van Dreunen; Margot van Spronsen; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2015-03-06       Impact factor: 9.941

Review 8.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

9.  The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome.

Authors:  Benedetta Costantini; Shahram Y Kordasti; Austin G Kulasekararaj; Jie Jiang; Thomas Seidl; Pilar Perez Abellan; Azim Mohamedali; Nicolas Shaun B Thomas; Farzin Farzaneh; Ghulam J Mufti
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

10.  CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Authors:  Michelle K Gleason; Julie A Ross; Erica D Warlick; Troy C Lund; Michael R Verneris; Andres Wiernik; Stephen Spellman; Michael D Haagenson; Alexander J Lenvik; Mark R Litzow; Pearlie K Epling-Burnette; Bruce R Blazar; Louis M Weiner; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.